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Background: Atherosclerosis is a chronic degenerative disease of the arteries and is thought to be one of the most
common causes of death globally. In recent years, the functions of adventitial fibroblasts in the development of
atherosclerosis and tissue repair have gained increased interests. LPS can increase the morbidity and mortality of
atherosclerosis-associated cardiovascular disease. Although LPS increases neointimal via TLR4 activation has been
reported, how LPS augments atherogenesis through acting on adventitial fibroblasts is still unknown. Here we
explored lipid deposition within adventitial fibroblasts mediated by lipopolysaccharide (LPS) to imitate inflammatory
conditions.
Results: In our study, LPS enhanced lipid deposition by the up-regulated expression of adipose
differentiation-related protein (ADRP) as the silencing of ADRP abrogated lipid deposition in LPS-activated
adventitial fibroblasts. In addition, pre-treatment with anti-Toll-like receptor 4 (TLR4) antibody diminished the
LPS-induced lipid deposition and ADRP expression. Moreover, LPS induced translocation of nuclear factor-κB
(NF-κB), which could markedly up-regulate lipid deposition as pre-treatment with the NF-κB inhibitor, PDTC,
significantly reduced lipid droplets. In addition, the lowering lipid accumulation was accompanied with the
decreased ADRP expression. Furthermore, LPS-induced adventitial fibroblasts secreted more monocyte
chemoattractant protein (MCP-1), compared with transforming growth factor-β1 (TGF-β1).
Conclusions: Taken together, these results suggest that LPS promotes lipid accumulation via the up-regulation of
ADRP expression through TLR4 activated downstream of NF-κB in adventitial fibroblasts. Increased levels of MCP-1
released from LPS-activated adventitial fibroblasts and lipid accumulation may accelerate monocytes recruitment
and lipid-laden macrophage foam cells formation. Here, our study provides a new explanation as to how bacterial
infection contributes to the pathological process of atherosclerosis.
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Atherosclerosis is considered to be one of the most com-
mon causes of death globally due to higher morbidity and
mortality in brain and heart, such as cerebral infarction.
Atherosclerosis is a chronic degenerative disease of the arter-
ies, representing the root cause of the majority of cardiovas-
cular disease (CVD) and their complications, including
coronary artery disease and myocardial infarction [1-3]. It is* Correspondence: bmlixian@gmail.com
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reproduction in any medium, provided the ora complex inflammatory process that is characterized by the
accumulation of lipids and fibrous elements in arteries [4].
In recent years, a relationship between adventitia and
atherosclerosis has garnered increasing interests [5,6].
Fibroblasts, as a major component of adventitia, are
thought to be the critical contributor to adventitial func-
tion in vascular inflammation, remodeling and neovascu-
larization. The action of this roles depend on the
secretion of many proinflammatory cytokines such as
interleukin (IL-6), reactive oxygen species (ROS) and
MCP-1, which are strongly correlated with advanced
atherosclerosis [7,8]. It has been demonstrated that re-
current injuries and repairs elicit the proliferation andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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teration in many chronic inflammatory diseases [9,10].
Although the importance of adventitial fibroblasts in
atherosclerosis has gained widespread acceptance, little
is known about the precise signaling pathways.
Lipopolysaccharide (LPS), a component of Gram-
negative bacteria cell walls, is thought to be involved in
cardiovascular disease as contribution to the develop-
ment of arterial plaques through activated proinflamma-
tory pathways [11-14]. Acting on adventitial fibroblasts,
LPS can cause intima hyperplasia via the activation of
the NF-κB pathway to secrete cytokines, including IL-6,
MCP-1 and tumor necrosis factor-α (TNF-α) [14]. Add-
itionally, injection of bacterial endotoxin-LPS in apolipo-
protein E (apoE)-deficient mice increases atherosclerotic
lesion size [11]. Toll-like receptors (TLRs) are key com-
ponents of the innate immune system in atherosclerosis-
based pathology. Deficiency in TLR4, the receptor of
LPS, reduces aortic atherosclerosis in apoE-deficient
mice [15]. Reduced atherosclerosis can also be observed
by injecting with melittin, which abolishes the expres-
sion of LPS-induced TNF-α and IL-1β and inhibits NF-
κB signal [16].
Lipid deposition is thought to be a major risk factor
for diseases ranging from obesity to atherosclerosis [7].
An excess of lipid-laden macrophage foam cells forma-
tion results from lipid overproduction and is a hall-
mark of atherosclerosis, forming the earliest detected
lesion, the fatty streak [4]. Aggressive lowering of lipid
levels markedly reduces atherosclerotic coronary lesion
and has thus attracted more attention as potential
therapeutic targets [17-19]. Adipose differentiation-
related protein (ADRP), a major lipid droplet protein,
regulates foam cell formation and atherosclerotic de-
velopment. Its absence severely restricts foam macro-
phage cell formation and attenuates atherosclerosis
[18,20].
To explore the role of adventitial fibroblasts in the
pro-atherosclerotic effects as lipid accumulation during
infection, we investigated whether LPS stimulation regu-
lated lipid accumulation via ADRP expression in adven-
titial fibroblasts, the related signal pathways and induced
MCP-1 were also analyzed in this process.Methods
Preparation of ox-LDL
Human LDL was obtained as described previously [21].
For the production of ox-LDL, 200 μg/ml LDL was
exposed to 20 μM CuSO4 in phosphate buffered saline
(PBS) for oxidation and the reaction was stopped with
40 μM butylhydroxytoluene in ethanol. The oxidized
LDL (CuoxLDL) was then dialyzed against culture
medium and sterilely filtered.Cell culture and treatments
Primary adventitial fibroblasts were isolated from human
aortas. All human material was obtained and processed
according to the recommendation of the Fourth Military
Medical University, China. The study was conducted in
compliance to the Helsinki Declaration, and all patients
gave written informed consent for publication of this re-
port. Isolated cells were cultured in stromal cell growth
medium (SCGM) containing 5% fetal bovine serum
(FBS), and maintained at 37°C and 5% CO2. Cells of pas-
sages 4 to 9 were used. These cells were obtained from
normal aortic tissue and their identity and purity were
confirmed based on morphology and growth characteris-
tics as previously described [22]. All tissue culture com-
ponents and solutions were purchased from Gibco BRL
(Paisley, UK).
Cells were treated with different stimuli and divided
into two groups. One group was treated with, or with-
out, LPS (10 μg/ml) (Sigma, St. Louis, MO) [21,23] or
TGF-β1 (10 μg/ml) (GenWay Biotech, San Diego, CA).
The other group was separately pre-treated with anti-
TLR4 antibody (10 μg/ml) (eBioscience, San Diego, CA)
for 2 h, 25 μM PDTC (NF-κB inhibitor, Calbiochem, La
Jolla, CA) for 2 h, and then exposed to 10 μg/ml LPS.
The normal adventitial fibroblasts were used as control
group cultured without any treatment. All cells were
incubated in the CO2 incubator before being used in
assays. After culturing for different time periods, cells
were harvested.
Lipid analysis by high-performance liquid
chromatography (HPLC)
Cellular total cholesterol (TC) and cholesterol ester (CE)
contents in treated and control cells were analyzed by
HPLC. Briefly, after incubation with CuoxLDL, cells
were washed 3 times by PBS, lysed by 0.9% NaOH solu-
tion and homogenized on ice for 10 seconds by ultra-
sound. Protein concentration was measured by the BCA
kit (Pierce, Rockford, IL). Then, an equal volume of
trichloroacetic acid was added and centrifuged at 800 × g
for 10 min. Masterol was used as a standard curve first,
and the extraction procedure was then repeated. The
samples were dissolved in 100 μl of isopropanol–
acetonitrile (v/v, 20:80), followed by incubation in an
ultrasound water bath at room temperature for 5 minutes.
Finally, the samples were placed in the Agilent 1100 series
HPLC (Agilent Technology, Palo Alto, CA).
Quantitative real-time PCR
Total cellular RNA was extracted from human adventitial
fibroblasts using TRIZOL reagent (Sigma). Total RNA
(~ 4 μg) was reverse transcribed to synthesize first strand
cDNA with the Oligo (dT) 18 primer using the cDNA
Synthesis Kit (Fermentas, St. Leon-Rot, Germany). Then,
Figure 1 LPS induced lipid deposition in the activated
adventitial fibroblasts. CuoxLDL was added to LPS-induced, or not,
cells. The ratio of CE/TC was used to evaluate lipid accumulation.
** P < 0.01.
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mixture with gene-specific primers (forward 50-TGCACT
CACCAAATCAGAGC-30 and reverse 50-AAGGGACC
TACCAGCCAGTT-30 for ADRP (GenBank accession no.
BC005127.2)). For normalization, β-actin mRNA was used.
SYBR Green I was used as the fluorochrome in real-time
PCR amplification. The reaction conditions followed the
instructions provided by the manufacturers of the SYBR
Premix Ex TaqTM II Kit (Takara Bio Inc., Otsu, Japan).
Western blotting
Immunoblotting analysis of ADRP was performed on
fibroblasts treated or not with LPS for 24 h. Briefly, har-
vested cells were washed twice with ice-cold PBS, lysed
with NE-PERTM or MEM-PERTM protein extraction
reagent (Pierce), and supplemented with a protease in-
hibitor cocktail (Sigma). The collected protein concen-
trations were determined by the BCA assay (Pierce) and
their proteins were electrophoresed on a 12% polyacryl-
amide gel and transferred onto a polyvinylidene difluor-
ide (PVDF) membrane. After blocking, the target
proteins were probed with anti-NF-κB p65 (1:1000) or
anti-ADRP (1:1000; Fitzgerald Industries Intl, Concord,
MA) overnight at 4°C, and then HRP-conjugated anti-
mouse antibodies (Sigma, St. Louis, Mo.) were added at
room temperature for 1 h. The bound antibodies were
visualized by using the LumiGLo reagent (Pierce) and
the levels of each protein relative to that of the β-actin
were analyzed.
Silencing of ADRP expression with small interference RNA
(siRNA)
To design target-specific siRNA, specific fragments of
ADRP and the Scramble II control were designed using
the internet tool of siRNA wizard (Invivogen, San Diego,
CA). The cDNA sequence of the Scramble II control
was 5’-AAGCGCGCUUUGUAGGAUUCG-3’ (21 nt).
The sense and antisense strands with two base over-
hangs were synthesized (GeneChem, Shanghai, China).
Human adventitial fibroblasts (6 × 105/ml) were trans-
fected with 2 μg/ml ADRP siRNA or Scramble II siRNA
using the GeneSilencer® siRNA transfection reagent
(GeneTherapy System, San Diego, CA), according to the
manufacturer’s instructions. About 24 h later, cells were
washed and then incubated with LPS for 24 h.
ELISA analysis
To evaluate the produced levels of MCP-1, either TGF-
β1 or LPS was added to the medium to induce fibroblast
differentiation. In short, cells were seeded at a density of
50 × 103 cells per well and stimulated for 24 h. The
supernatant was harvested and the expression levels of
MCP-1 were detected by the Human MCP-1 ELISA Kit(R&D Systems, Minneapolis, MN) according to the man-
ufacturer’s instructions.
Data analysis
Data were analyzed using SPSS 11.0 software. A typical
image from at least three similar experiments was
presented. Statistical analysis was carried out using
t-tests. P < 0.05 was considered statistically significant.
All results are expressed as mean ±SD.
Results
LPS-stimulation enhanced lipid accumulation
LPS is a major contributor to the development of arterial
plaques through activated proinflammatory pathways
[11-14]. To ascertain whether LPS can induce lipid de-
position in adventitial fibroblasts, CuoxLDL was added
and the ratio of CE/TC was used to analyze lipid accu-
mulation. As shown in Figure 1, the values of CE/TC
were 10.1±3.5% in the CuoxLDL control group and 47.2
±6.2% in the LPS-CuoxLDL group. This showed that
LPS-stimulated adventitial fibroblasts accelerated the
uptake of CuoxLDL and promoted cholesterol ester de-
position, compared to the control group.
LPS induced the lipid deposition via up-regulating the
expression of ADRP in adventitial fibroblasts
As a major lipid droplet protein, ADRP plays crucial roles
in regulating foam cell formation and atherosclerotic de-
velopment, and is abundant in lipid-laden cells [18,20].
Therefore, to understand that how LPS promotes lipid ac-
cumulation, ADRP was analyzed here. After stimulation
with LPS for different time periods, ADRP mRNA and cel-
lular protein levels were analyzed by real-time PCR and
Western blotting, respectively. Compared to the control
group, a significant up-regulation of ADRP mRNA was
confirmed at 8 h after LPS stimulation, which then grad-
ually decreased (Figure 2A). Consistent with the above ob-
servation, LPS also induced a rapid increase in ADRP
protein level (Figure 2B), but this lagged behind the
Figure 2 LPS up-regulated the expression levels of ADRP mRNA and protein. After stimulation with, or without, LPS (10 μg/ml) for 0 to 48
hours, ADRP mRNA and protein levels were analyzed. (A) LPS-induced expression of ADRP mRNA. (B) The corresponding protein levels of ADRP
in LPS-induced fibroblasts. ** P < 0.01. *P < 0.05.
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protein was notably induced by LPS stimulation and was
about 3.5-fold higher than that of the untreated group at
48 h. All mRNA and protein level analyses showed that
LPS significantly enhanced the expression of ADRP
mRNA and protein.
Whether ADRP is the contributor to lipid accumulation
during LPS stimulation, to address this question, the ex-
pression of ADRP was silenced by siRNA targeting ADRP
and western blotting was used to evaluate the silencing ef-
fect of ADRP in LPS-activated cells. As shown in
Figure 3A, most of the expression of ADRP was silenced;
the absence of ADRP strikingly reduced lipid accumula-
tion and the ratio of CE/TC. However, the ratio of CE/TC
in the ADRP siRNA pre-treated cells was still higher thanthat of the LPS-untreated group (Figure 3B). All of these
results suggested that LPS could promote lipid deposition
via the up-regulating ADRP expression, but it was not the
only molecule involved in this process.LPS-induced lipid deposition depended on the activation
of TLR4 and NF-κB pathway
As a receptor of LPS, TLR4 and its downstream signal-
ing effectors, NF-κB, are pivotal in the initiation and de-
velopment of atherosclerosis [15,24]. The intra-nuclear
NF-κB p65 and control histone were characterized by
Western blotting. The intra-nuclear translocation of NF-
κB was obviously observed following LPS stimulation. At
the same time, significant inhibition of NF-κB activation
Figure 3 Silencing of ADRP decreased lipid deposition in LPS-
activated fibroblasts. Cultured cells were transfected with 2 μg/ml
of ADRP siRNA or Scramble II siRNA before exposure to LPS. The
effect of silencing ADRP was analyzed by Western blotting (A) and
the resulting lipid accumulation was characterized by HPLC (B).
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tor, PDTC (Figure 4A).
To analyze whether lipid accumulation was correlated
with the activation of TLR4 and the downstream NF-κB
pathway, real-time PCR was used here (Figure 4B). Ob-
viously, pretreatment with the anti-TLR4 antibody sig-
nificantly decreased lipid deposition in adventitial
fibroblasts, suggesting that TLR4 was essential for LPS-
induced lipid droplets. Furthermore, pretreatment with
PDTC resulted in a corresponding attenuated lipid de-
position in LPS-activated adventitial fibroblasts, com-
pared with DMSO control (Figure 4B). As shown in
Figure 4C, the lipid accumulation was accompanied with
ADRP expression during LPS activated pathway. These
results confirmed that the LPS could induce lipid depos-
ition via ADRP expression through TLR4 and NF-κB sig-
naling pathway in adventitial fibroblasts.
Higher amounts of MCP-1 were induced by LPS than TGF-
β1 treatment
As described previously, activated adventitial fibroblasts
can produce many cytokines and chemokines to affect
the development of atherosclerosis [7,8]. Lots produc-
tion of MCP-1 are induced by LPS and TGF-β1 stimula-
tion in adventitial fibroblasts. To evaluate the activatingability of LPS and TGF-β1 on adventitial fibroblasts, the
induced expression of MCP-1 was determined by ELISA
analysis (Figure 5). Compared to the control group, LPS
induced a statistically significant up-regulation of MCP-
1 expression and a higher amount of MCP-1 was
detected in the LPS-treated group compared to the
TGF-β1 one. This showed that LPS could more easily
induce the expression of MCP-1 than TGF-β1 in acti-
vated adventitial fibroblasts.
Discussion
Atherosclerosis is the major risk factor for human
health, the related diseased has resulted in high mortal-
ity, including cerebral infarction and complications of
cardiovascular disease [1]. Atherosclerosis is charac-
terized with the accumulation of lipids and fibrous
elements. Adventitial fibroblasts can transform into
activated myofibroblasts, which have the ability to
proliferate and migrate to the vascular lumen by the
induced production of proinflammatory cytokines,
chemokines and extracellular matrix (ECM). This
switch of fibroblasts into myofibroblasts is important
for vascular repair and atherosclerotic plaques forma-
tion [4,6,25]. Many factors can activate the transform-
ation of adventitial fibroblasts into myofibroblasts. LPS,
as one of these factors, has been discussed in many
reports [26,27]. An epidemiological survey confirms
that Gram-negative bacteria may increase the morbid-
ity and mortality of atherosclerosis-associated cardio-
vascular disease [21,28,29]. Many factors can serve as
a mediator/inducer of atherosclerosis by interaction
with a common inflammation pathway-TLR4, includ-
ing heat shock protein (HSP60) and LPS [11,30]. As a
common ligand of TLR4, LPS is considered as crucial
for the initiation and development of atherosclerosis
[11-14]. However, LPS involvement in lipid accumula-
tion in adventitial fibroblasts has not been reported.
Here, we studied the molecular mechanism underlying
LPS-mediated lipid accumulation and speculated the
possible correlation between activated adventitial fibro-
blasts and the formation of foam cells.
Lipid deposition is a trigger for atherosclerosis and
complications [7,18,19]. Foam cells are major compo-
nents of atherosclerotic plaques and their formation
mainly depends on lipid accumulation [31,32]. The chol-
esterol in foam cells is present mainly as cytoplasmic
cholesteryl ester and marked accumulation of CE results
in foam cell formation [33,34]. Genetic ablation of neu-
tral CE hydrolase 1 (Nceh1) promotes foam cell forma-
tion and aggravates atherosclerosis in mice [35]. ADRP,
as a PAT-domain protein, can promote lipid accumula-
tion in macrophages and lipid-laden cells formation
[18,20]. Oxidative modification of LDL is considered to
promote arterial lipid accumulation and atherosclerosis
Figure 4 The induced lipid accumulation resulted from up-regulated expression of ADRP via LPS-activated TLR4 and NF-κB pathway.
Cultured adventitial fibroblasts were pretreated with or without anti-TLR 4 antibodies and the NF-κB inhibitor PDTC for 1 h before exposure to 10
μg/ml of LPS for 48 h. Compared to the control group, treatment with the inhibitors significantly abrogated the LPS-induced increase in ADRP
expression and lipid deposition. (A) The activation and inhibition of NF-κB pathway was analyzed by Western blotting. Cultured cells were
pretreated with, or without, NF-κB inhibitor PDTC before LPS stimulation. (B) Induced lipid accumulation via the LPS-activated TLR4 and NF-κB
pathway. (C) The induced lipid accumulation was accompanied with ADRP expression. The expression of ADRP mRNA in activated, or not, cells
were analyzed by real-time PCR. ** P < 0.01. *P < 0.05.
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could accelerate the ingestion of CuoxLDL and ultim-
ately promote CE accumulation through a drastic in-
crease in ADRP expression, but this was not the only
molecule involved in LPS-mediated lipid deposition as
the lipid droplet amount in ADRP-siRNA treated cells
was still higher than that of LPS-untreated group.As lots of CE production is more prone to form foam
cells and is critical for atherosclerotic plaque induction.
So it is very necessary for us to clarify that which signal-
ing pathway was involved in LPS-mediated lipid accu-
mulation. As the absence of the downstream adaptor
molecule TLR4 is associated with reduced atheroscler-
otic plaque formation via the down-regulation of MCP-
Figure 5 Induced secretion of MCP-1 in activated adventitial
fibroblasts pretreated with either LPS or TGF-β1. The cells were
incubated with, or without, the same concentration of stimuli for 24
h. The concentration of MCP in the cultured medium was
determined by ELISA. Results are mean ±SD. *P < 0.05 compared to
control cells (NC).
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dress this question, TLR4 and its downstream signaling
effectors, NF-κB, were investigated here. As a receptor
of LPS, TLR4 is pivotal in the initiation and development
of atherosclerosis [15,24]. An obvious correlation between
lipid droplets and TLR4-NF-κB pathway was confirmed,
because pre-treatment with anti-TLR4 antibody and
PDTC inhibitor significantly abrogated the lipid depos-
ition in LPS-activated adventitial fibroblasts. In addition,
LPS-induced lipid accumulation is accompanied with
ADRP expression during this process. Thus, it appears
that LPS promotes lipid accumulation by increasing
ADRP expression through TLR4 and activated down-
stream NF-κB pathway.
During atherosclerosis, the chemokine MCP-1 is an
important component in the initiation of atherosclerotic
plaques. It is widely accepted that MCP-1 can recruit
monocytes by the surface receptor CCR2, accelerate
cellular infiltration of lymphocytes and characteristically
accumulate in nascent atheroma [37,38]. A mutant lack-
ing MCP-1 or its receptor CCR2 shows striking decreases
in mononuclear phagocyte accumulation and local lipid
levels [39,40]. Many factors can activate the production
of MCP-1, such as LPS, TGF-β1 and angiotensin. TGF-
β1 is an important immunomodulatory cytokine which
can significantly stimulate the expression of MCP-1 in
fibroblast cells [41]. LPS can induce MCP-1 up-regulation
by the activated NF-κB signaling pathway in fibrocyte
[42]; the inhibition of this pathway results in a strong de-
crease in vitro [43]. However, there is no report about the
comparative analysis of the two inducers regarding MCP-
1 production. In this study, we found that LPS could
strongly induce more secretion of MCP-1 in activated ad-
ventitial fibroblasts than TGF-β1, indicating that more
monocytes could be recruited to regulate lipid accumula-
tion by the transformation into macrophages.Conclusions
It is well known that lipid accumulation and activated
macrophages are the basis of foam cells formation,
which are triggers for atherosclerotic plaque production
[7,17,31]. LPS can up-regulate the expression of Fcamr
(Fc α/μ receptor) through activated NF-κB and the p38
MAPK pathway to increase the formation of lipid-laden
foam cells [21]. Here, LPS stimulation can activate TLR4
in adventitial fibroblasts, thereby increasing ADRP ex-
pression through the NF-κB pathway to promote lipid
accumulation. The absence of TLR4 can reduced athero-
sclerotic plaque formation via the down-regulation of
MCP-1 [15]. MCP-1 can recruit monocytes and promote
lipid-laden foam cells formation, lots of MCP-1 produc-
tion was detected in LPS-stimulated cells in our study.
Based on these results, we can conclude that LPS can in-
duce lipid-laden foam cells formation via MCP-1 pro-
duction and lipid deposition by TLR4-NF-κB pathway,
and accelerate the pathogenesis of atherosclerosis. Taken
together, our work may provide a new understanding
about why bacterial infection increases the mortality of
atherosclerosis-related cardiovascular diseases. In recent
years, the NF-κB pathway has attracted increasing atten-
tion as a drug-development target for treating inflamma-
tory diseases [44]. Thus, future studies should focus on
how to slow down the development of atherosclerosis by
targeting the bioactive molecules involved in the NF-κB
pathway, such as ADRP.Abbreviations
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